Form 4/A for BLFS BIOLIFE SOLUTIONS INC
Accepted 2025-03-20 00:00:00 ET · period of report 2025-03-17 · accession 0001628280-25-014185 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2025-03-20 | 2025-03-17 | BLFS | Aebersold Sarah | CHRO | S - Sale | $25.44 | -2,695 | 48.8K | -5% | -$68.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-17 | S | D | 2,695 | $25.44 | 48,797 | D | — | — | (F2) This Form 4 amendment has been filed to correct the amount of securities reported in a Form 4 filed on March 18, 2025. The Form 4 included a sale of 5,632 shares that was improperly included under the reporting person. The correct amount of securities should have been reported as 2,695 in the Form 4. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.90 to $25.97, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |